Compare RPC & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RPC | SLBT |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.2M | 942.1M |
| IPO Year | 2021 | 2025 |
| Metric | RPC | SLBT |
|---|---|---|
| Price | $7.50 | $1.66 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $12.75 | N/A |
| AVG Volume (30 Days) | ★ 480.4K | 108.5K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 6.25 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $297,346,000.00 | N/A |
| Revenue This Year | $20.02 | N/A |
| Revenue Next Year | $16.79 | N/A |
| P/E Ratio | $52.44 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $6.79 | $1.42 |
| 52 Week High | $9.51 | $6.25 |
| Indicator | RPC | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 35.86 |
| Support Level | $7.54 | N/A |
| Resistance Level | $8.02 | $3.36 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 39.47 | 32.89 |
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.